A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.

Key facts

Study ID

NCT07733089

Run by

Zealand Pharma

People needed

32

Starts

2026-07-22

Expected to finish

2027-04-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months).
• Participants who have ≥ 2 vulgar psoriatic plaques.
• BMI within the range 18.0-35.0 kg/m2 (inclusive).
• Further inclusion criteria apply.

You may not qualify if…

• Erythrodermic, predominantly guttate, exclusively palmar/plantar, or generalized pustular psoriasis.
• Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate).
• Any clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hematology, biochemistry, and urinalysis).
• Any clinically significant abnormal findings during the standardized neurological examination conducted at screening.
• Use of any concurrent systemic medications that could affect psoriasis or psoriasis evaluation, including corticosteroids, retinoids, cyclosporine, methotrexate, PDE4s (phosphodiesterase 4), or biologic agents within 30 days prior to IMP administration or planned to use during the course of the trial.
• Use of concurrent topical medications containing corticosteroids, retinoids, calcitriol or other topical medication relevant to psoriasis treatment (must be discontinued at least 2 weeks prior to baseline).
• Use of any biologic or advance systemic therapies for any autoimmune disease within the last 12 months.
• Use of UVA, PUVA, or UVB therapy and tanning beds within 4 weeks of baseline or during trial participation.
• Further exclusion criteria apply.

Where it is running

• Centre for Human Drug Research — Leiden, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.